Sulbactam sodium Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Sulbactam sodium Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
42
Registered trials
1
Result records
34
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Sulbactam sodium can convert its Small molecule drug profile and β-lactamase biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Sulbactam sodium (query alias: sulbactam durlobactam) |
|---|---|
| Modality / target | Small molecule drug; β-lactamase; β-lactamase inhibitors |
| Highest global status | Approved |
| Originator | Harbin Pharmaceutical Group Co., Ltd. |
| Active developers | Harbin Pharmaceutical Group Co., Ltd., Hebei Medical University |
The MCP disease footprint includes Bacterial Infections, Alzheimer Disease. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| JPRN-jRCTs071250072 | Phase 4 | Recruiting | 160 | The clinical cure rate at the time of test-of-cure (TOC) in study participants treated with either lascufloxacin switch therapy (switching from 150 mg intravenous infusion to 75 mg oral tablets) or standard therapy with ampicillin/sulbactam intravenous infusion. |
| JPRN-jRCTs051260063 | Phase 3 | 募集中 | 320 | Incidence of surgical site infection (SSI) within 30 days |
| CTRI/2025/09/094280 | Phase 3 | Not Yet Recruiting | 126 | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
Phase 3; n=207; evaluation: not stated. Reported fields: Proportion of Patients With All-Cause Mortality in CRABC m-MITT Population = 12 Participants ; Proportion of Patients With All-Cause Mortality in CRABC m-MITT Population = 20 Participants ; Proportion of Patients With All-Cause Mortality in CRABC m-MITT Population: Mean Difference (Final Values) = -13.2(95% CI, -30 to 3.5)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Sulbactam sodium addresses Bacterial Infections, Alzheimer Disease. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 34 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: β-lactamase records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-06-16 | Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets | Approved | Financial terms not disclosed |
| 2025-08-14 | Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic | Phase 1 | US$325.0M stated total |
| 2025-08-07 | CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team | Approved | US$300.0M upfront; US$25.0M milestones; US$325.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Preparation method of sulbactam sodium”. The milestone feed surfaced a patent-application signal described as “Preparation process of sulbactam sodium”. The milestone feed surfaced a patent-application signal described as “Combination compositions comprising a beta-lactamase inhibitor”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
